Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease

Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.

Recent articles in left column more or less in alphabetical order classified

Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.

If you want to support us you can do so through a donation: See registration OPS

Overview Study in Lymphoma: A survey of 37 case studies with multiple cancers in a study group of 810 patients with lymphoma and how certain formal approach worked or not and gives good insight into the different types of lymphoma involving other organs also by cancer were affected, with or without other forms of primary cancer or metastases. Update November 27, 2010

October 31, 2005: Source: The Oncologist

In the following study, Greek oncologists investigated the effect of approach of lymphoma which has at least two other parts of the body already has spread.

Between May 1994 and December 2002 were 810 patients with a particular form of disseminated lymphoma diagnosed and treated in several Greek hospitals. In 37 patients of this group lymfklierkankerpatiënten Observed side-primary lymphoma are at least two other places in the body (other body) had tumors by whether or not metastases. This group of 37 patients followed for eight years to see what the ultimate impact on survival and time to recurrence of the proposed treatments.

Of the 37 patients, 28 received only chemotherapy (an anthracycline based regimen), while nine patients also received surgery followed by chemotherapy. (Editors note: See also lymphoma information for studies and effects of specific chemotherapy for lymphoma in alphabetical list under chemo and lymphoma.)

This Greek study offered chemotherapy given: CHOP / CEOP / CNOP (cyclophosphamide, doxorubicin [Adriamycin ®, and / or mitoxantrone, and / or vincristine and / or prednisone, three patients received a combination of fludarabine (Fludara ®;) and mitoxantrone, three patients received a combination of CEOP with monoclonal agent rituximab and one patient refused further treatment after surgery.

The results:
Response = response to treatment and survival time:
34 patients were available for evaluation of response (response). Three patients could not be evaluated for the following reasons: 1 patient refused treatment (n = 1) and two at the contact was lost during the follow-up period (n = 2).

After the start of treatment was a complete remission in 21 patients (57%), partial remission (PR) was achieved in 6 patients (16%) and 7 patients (19%) gave no response. The median (average) overall survival time for all patients was 71.8 months (range, 3.8-132.1), and median time to recurrence (return of cancer) was 25.9 months (range, 2.7-132.1)

We read not whether these results are good or conform to what would be expected compared with historical results and study such an approach. It is called the sense that the results are not statistically significant but which it refers than we dare not say. We do know from experience of other types of lymphoma patients with a change of lifestyle, diet and certain nutrients a very good result can be achieved, especially on the quality of life and acting on time to a recurrence, which often in lymphoma occurs. Now it is true that this study only patients with already two or more metastases were followed so all in stage IV (= incurable) traffic. But still it seems advisable if you suffer diagnosed with lymphoma to be well informed before you start chemotherapy. The lymphatic system in man takes care of our waste processing, etc. and is extremely sensitive to toxic substances, but also good for natural substances. Many pure spring water and drink plenty of fruit and vegetables and no sugar, etc. like lymphoma in an additional good or sometimes even single treatment option. Read below and nutrients in food and lymphoma information for several study results with it.

Here a few quotes from an English study, full report including tables etc. which I have quoted and that full English report can be read at: The Oncologist

. The Oncologist, Vol. 10, no. 9, 734-738, October 2005, doi: © 2005 10.1634/theoncologist.10-9-734 Alphamed Press Multifocal Extranodal Non-Hodgkin's Lymphoma: A Clinicopathologic Study of 37 Cases in Greece, a Hellenic Cooperative Oncology Group Study Economopoulosa Theofanis, Sotirios Papageorgioua, Dimitra Rontogiannib, Vassiliki Kaloutsic, George Fountzilasc, Constantinos Tsatalasd, Nikolaos Pavlidis, Dimitrios Pectasidesa, Efstathios Papageorgioua, Meletios Dimopoulosf a Second Department of Internal Medicine, Athens University, University General Hospital "Attikon," Haidari, Greece b Pathology Department, Evangelismos Hospital, Athens, Greece c AHEPA Hospital, Aristotle University, Thessaloniki, Greece, dUniversity Hospital, Alexandroupolis, Greece, e Medical Oncology Department, Ioannina University, Ioannina, Greece f Department of Clinical Therapeutics, University of Athens, Athens, Greece

Correspondence: Correspondence: T. Economopoulos, University General Hospital "Attikon," 1 Rimini Str., 124 62 Haidari, Greece. Telephone: 30-210-5831255, Fax: 30-210-5326450 e-mail: sotirispapageorgiou@hotmail.com

The purpose of this retrospective study was to Illustrate the clinicopathological features of Patients presenting with multifocal extranodal non-Hodgkin's lymphoma (NHL). Among 810 patients with NHL, 37 cases (4.2%) Were found to have multiple extranodal involvement (two or more sites). Were there 24 people and 13 women, with a median age of 63 years. The Majority of These cases (n = 26) had gastric or intestinal (GI) involvement with or Without Other extranodal sites. Lung alongwith another extranodal site was Relatively common in the present series. Stratification of the 37 Cases According To the International Prognostic Index (IPI) showed 89% of the Patients That belonged to the high-risk groups. Diffuse large B-cell lymphoma (DLBCL) accounted for 62%, and mucosa-associated lymphoma tissue (MALT) lymphoma accounted for 27% of all cases. After induction treatment with anthracycline-based regimens, complete remission was Achieved in 21 patients (57%), partial remission was Achieved in six patients (16%), and seven patients (19%) had no response, while three patients (8% ) Were nonevaluable. In Conclusion, multifocal extranodal NHL is a heterogeneous group of diseases. The Majority of Them Various Artists Arise at sites in the GI tract. DLBCL was the must frequent histological subtype followed by MALT lymphoma. Risk group, as defined by the IPI, was predictive of survival.